Andrei V Alexandrov1, Martin Köhrmann2, Lauri Soinne3, Georgios Tsivgoulis4, Andrew D Barreto5, Andrew M Demchuk6, Vijay K Sharma7, Robert Mikulik8, Keith W Muir9, Gordon Brandt10, John Alleman10, James C Grotta11, Christopher R Levi12, Carlos A Molina13, Maher Saqqur14, Dimitris Mavridis15, Theodora Psaltopoulou16, Milan Vosko17, Jochen B Fiebach18, Pitchaiah Mandava19, Thomas A Kent19, Anne W Alexandrov20, Peter D Schellinger21. 1. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: avalexandrov@att.net. 2. Department of Neurology, Universitätsklinikum Erlangen, Erlangen, Germany; Department of Neurology, University Duisburg-Essen, Essen, Germany. 3. Department of Neurology, Helsinki University Hospital and Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland. 4. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA; Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; International Clinical Research Center and Department of Neurology, St Anne's University Hospital in Brno, Brno, Czech Republic. 5. Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA. 6. Department of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. 7. Yong Loo Lin School of Medicine, National University of Singapore and Division of Neurology, Department of Medicine, National University Hospital, Singapore. 8. International Clinical Research Center and Department of Neurology, St Anne's University Hospital in Brno, Brno, Czech Republic; Medical Faculty, Masaryk University, Brno, Czech Republic. 9. Institute of Neuroscience and Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK. 10. Cerevast Therapeutics, Redmond, WA, USA. 11. Clinical Innovation and Research Institute, Memorial Hermann Hospital-Texas Medical Center, Houston, TX, USA. 12. Department of Neurology, John Hunter Hospital, University of Newcastle, Newcastle, NSW, Australia. 13. Stroke Unit, Department of Neurology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain. 14. Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada; Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar. 15. Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece; Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece. 16. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 17. Department of Neurology, Kepler University Clinic, General Hospital Linz (AKH), Linz, Austria. 18. Center for Stroke Research Berlin, Charité-University Medicine Berlin, Berlin, Germany. 19. Stroke Outcomes Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX, USA; Michael E DeBakey VA Medical Center Stroke Program and Center for Translational Research on Inflammatory Diseases, Houston, TX, USA. 20. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA; Australian Catholic University, Sydney, NSW, Australia. 21. Departments of Neurology and Neurogeriatry, John Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany.
Abstract
BACKGROUND:Pulsed-wave ultrasound increases the exposure of an intracranial thrombus to alteplase (recombinant tissue plasminogen activator), potentially facilitating early reperfusion. We aimed to ascertain if a novel operator-independent transcranial ultrasound device delivering low-power high-frequency ultrasound could improve functional outcome in patients treated with alteplase after acute ischaemic stroke. METHODS: We did a multicentre, double-blind, phase 3, randomised controlled trial (CLOTBUST-ER) at 76 medical centres in 14 countries. We included patients with acute ischaemic stroke (National Institutes of Health Stroke Scale score ≥10) who received intravenous thrombolysis (alteplase bolus) within 3 h of symptom onset in North America and within 4·5 h of symptom onset in all other countries. Participants were randomly allocated (1:1) via an interactive web response system to either active ultrasound (2 MHz pulsed-wave ultrasound for 120 min [sonothrombolysis]; intervention group) or sham ultrasound (control group). Ultrasound was delivered using an operator-independent device, which had to be activated within 30 min of the alteplase bolus. Participants, investigators, and those assessing outcomes were unaware of group assignments. The primary outcome was improvement in the modified Rankin Scale score at 90 days in patients enrolled within 3 h of symptom onset, assessed in the intention-to-treat population as a common odds ratio (cOR) using ordinal logistic regression shift analysis. This trial is registered with ClinicalTrials.gov, number NCT01098981. The trial was stopped early by the funder after the second interim analysis because of futility. FINDINGS:Between August, 2013, and April, 2015, 335 patients were randomly allocated to the intervention group and 341 patients to the control group. Compared with the control group, the adjusted cOR for an improvement in modified Rankin Scale score at 90 days in the intervention group was 1·05 (95% CI 0·77-1·45; p=0·74). 51 (16%) of 317 patients in the intervention group and 44 (13%) of 329 patients in the control group died (unadjusted OR 1·24, 95% CI 0·80-1·92; p=0·37) and 83 (26%) and 79 (24%), respectively, had serious adverse events (1·12, 0·79-1·60; p=0·53). INTERPRETATION:Sonothrombolysis delivered by an operator-independent device to patients treated with alteplase after acute ischaemic stroke was feasible and most likely safe, but no clinical benefit was seen at 90 days. Sonothrombolysis could be further investigated either in randomised trials undertaken in stroke centres that are dependent on patient transfer for endovascular reperfusion therapies or in countries where these treatments cannot yet be offered as the standard of care. FUNDING: Cerevast Therapeutics.
RCT Entities:
BACKGROUND: Pulsed-wave ultrasound increases the exposure of an intracranial thrombus to alteplase (recombinant tissue plasminogen activator), potentially facilitating early reperfusion. We aimed to ascertain if a novel operator-independent transcranial ultrasound device delivering low-power high-frequency ultrasound could improve functional outcome in patients treated with alteplase after acute ischaemic stroke. METHODS: We did a multicentre, double-blind, phase 3, randomised controlled trial (CLOTBUST-ER) at 76 medical centres in 14 countries. We included patients with acute ischaemic stroke (National Institutes of Health Stroke Scale score ≥10) who received intravenous thrombolysis (alteplase bolus) within 3 h of symptom onset in North America and within 4·5 h of symptom onset in all other countries. Participants were randomly allocated (1:1) via an interactive web response system to either active ultrasound (2 MHz pulsed-wave ultrasound for 120 min [sonothrombolysis]; intervention group) or sham ultrasound (control group). Ultrasound was delivered using an operator-independent device, which had to be activated within 30 min of the alteplase bolus. Participants, investigators, and those assessing outcomes were unaware of group assignments. The primary outcome was improvement in the modified Rankin Scale score at 90 days in patients enrolled within 3 h of symptom onset, assessed in the intention-to-treat population as a common odds ratio (cOR) using ordinal logistic regression shift analysis. This trial is registered with ClinicalTrials.gov, number NCT01098981. The trial was stopped early by the funder after the second interim analysis because of futility. FINDINGS: Between August, 2013, and April, 2015, 335 patients were randomly allocated to the intervention group and 341 patients to the control group. Compared with the control group, the adjusted cOR for an improvement in modified Rankin Scale score at 90 days in the intervention group was 1·05 (95% CI 0·77-1·45; p=0·74). 51 (16%) of 317 patients in the intervention group and 44 (13%) of 329 patients in the control group died (unadjusted OR 1·24, 95% CI 0·80-1·92; p=0·37) and 83 (26%) and 79 (24%), respectively, had serious adverse events (1·12, 0·79-1·60; p=0·53). INTERPRETATION: Sonothrombolysis delivered by an operator-independent device to patients treated with alteplase after acute ischaemic stroke was feasible and most likely safe, but no clinical benefit was seen at 90 days. Sonothrombolysis could be further investigated either in randomised trials undertaken in stroke centres that are dependent on patient transfer for endovascular reperfusion therapies or in countries where these treatments cannot yet be offered as the standard of care. FUNDING: Cerevast Therapeutics.
Authors: Nirav Dhanesha; Thomas Schnell; Salam Rahmatalla; Jonathan DeShaw; Daniel Thedens; Bradley M Parker; M Bridget Zimmerman; Andrew A Pieper; Anil K Chauhan; Enrique C Leira Journal: Stroke Date: 2020-05-13 Impact factor: 7.914
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Andrei V Alexandrov; Georgios Tsivgoulis; Martin Köhrmann; Aristeidis H Katsanos; Lauri Soinne; Andrew D Barreto; Travis Rothlisberger; Vijay K Sharma; Robert Mikulik; Keith W Muir; Christopher R Levi; Carlos A Molina; Maher Saqqur; Dimitris Mavridis; Theodora Psaltopoulou; Milan R Vosko; Jochen B Fiebach; Pitchaiah Mandava; Thomas A Kent; Anne W Alexandrov; Peter D Schellinger Journal: Ther Adv Neurol Disord Date: 2019-07-12 Impact factor: 6.570
Authors: Georgios Tsivgoulis; Maher Saqqur; Vijay K Sharma; Alejandro Brunser; Jürgen Eggers; Robert Mikulik; Aristeidis H Katsanos; Theodore N Sergentanis; Konstantinos Vadikolias; Fabienne Perren; Marta Rubiera; Reza Bavarsad Shahripour; Huy Thang Nguyen; Patricia Martínez-Sánchez; Apostolos Safouris; Ioannis Heliopoulos; Ashfaq Shuaib; Carol Derksen; Konstantinos Voumvourakis; Theodora Psaltopoulou; Anne W Alexandrov; Andrei V Alexandrov Journal: J Stroke Date: 2020-01-31 Impact factor: 6.967
Authors: Robert T Kleven; Kunal B Karani; Nicole Hilvert; Samantha M Ford; Karla P Mercado-Shekhar; John M Racadio; Marepalli B Rao; Todd A Abruzzo; Christy K Holland Journal: Sci Rep Date: 2021-02-17 Impact factor: 4.379
Authors: Julia Masomi-Bornwasser; Axel Heimann; Christian Schneider; Tristan Klodt; Hammoud Elmehdawi; Andrea Kronfeld; Harald Krenzlin; Yasemin Tanyildizi; Karl-Friedrich Kreitner; Oliver Kempski; Clemens Sommer; Florian Ringel; Naureen Keric Journal: J Clin Med Date: 2021-02-03 Impact factor: 4.241